Diagnostics & Imaging
Elucid FFR-IQ
FDA-cleared coronary CT angiography analysis estimating fractional flow reserve without invasive pressure-wire measurement.
The Signal
FFR-IQ (B.1) received 510(k) clearance under K262015 on September 29, 2026. Its company-described BioIntegrated approach supports physician evaluation of coronary physiology alongside imaging and other clinical information.
Company profileMore in Diagnostics & Imaging
Aidoc
AI platform that flags acute abnormalities in medical imaging to prioritize urgent patient scans.
View toolViz.ai
AI powered care coordination platform that detects stroke and other acute diseases on imaging.
View toolLunit
AI software for detecting abnormalities in chest radiographs and breast mammography scans.
View toolPaige AI
Digital pathology platform utilizing AI to assist pathologists in diagnosing cancer from tissue slides.
View tooliRhythm Zio
Continuous cardiac monitoring service utilizing wearable biosensors and AI to detect arrhythmias.
View toolHeartFlow
Non invasive personalized cardiac test modeling blood flow in coronary arteries from CT scans.
View tool